Abbott Laboratories (ABT) : Alpha Omega Wealth Management scooped up 475 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 21, 2016. The investment management firm now holds a total of 575 shares of Abbott Laboratories which is valued at $25,346.Abbott Laboratories makes up approximately 0.02% of Alpha Omega Wealth Management’s portfolio.
Abbott Laboratories closed down -0.05 points or -0.11% at $43.83 with 50,35,092 shares getting traded on Wednesday. Post opening the session at $43.93, the shares hit an intraday low of $43.69 and an intraday high of $44 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Other Hedge Funds, Including , Strs Ohio sold out all of its stake in ABT during the most recent quarter. The investment firm sold 1,389,606 shares of ABT which is valued $61,253,832.Yhb Investment Advisors reduced its stake in ABT by selling 1,339 shares or 3.55% in the most recent quarter. The Hedge Fund company now holds 36,429 shares of ABT which is valued at $1,605,790. Abbott Laboratories makes up approx 0.43% of Yhb Investment Advisors’s portfolio.Stonebridge Capital Management Inc boosted its stake in ABT in the latest quarter, The investment management firm added 2,000 additional shares and now holds a total of 19,333 shares of Abbott Laboratories which is valued at $839,246. Abbott Laboratories makes up approx 0.35% of Stonebridge Capital Management Inc’s portfolio. Wunderlich Securities sold out all of its stake in ABT during the most recent quarter. The investment firm sold 5,456 shares of ABT which is valued $236,845.Burns J W Co Incny reduced its stake in ABT by selling 700 shares or 3.25% in the most recent quarter. The Hedge Fund company now holds 20,865 shares of ABT which is valued at $886,345. Abbott Laboratories makes up approx 0.28% of Burns J W Co Incny’s portfolio.
On the company’s financial health, Abbott Laboratories reported $0.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Apr 20, 2016. Analyst had a consensus of $0.39. The company had revenue of $4885.00 million for the quarter, compared to analysts expectations of $4777.68 million. The company’s revenue was down -.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.47 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Company shares were Reiterated by RBC Capital Mkts on Apr 11, 2016 to “Outperform”, Firm has raised the Price Target to $ 48 from a previous price target of $45 .Shares were Reiterated by RBC Capital Mkts on Jan 29, 2016 to “Outperform” and Lowered the Price Target to $ 45 from a previous price target of $51 .
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.